Sign in
Not yet recruitingPhase 3

Alpha-Lipoic Acid Added to Dapagliflozin and Insulin Resistance in Type 2 Diabetes

Key facts

Who runs it
Fayoum University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
70 people, planned
Starts
1 Dec 2026
Expected to end
1 Sept 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Alpha-Lipoic Acid (ALA)
  • Placebo
Record updated
12 November 2026

Who can take part

Age
30 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Adults aged 30 to 70 years, either sex
  • Established diagnosis of type 2 diabetes mellitus
  • HbA1c between 7.0% and 10.0% at screening
  • On stable metformin plus dapagliflozin 10 mg daily for at least 3 months
  • Able and willing to give written informed consent

Who cannot take part

  • Type 1 diabetes or secondary forms of diabetes
  • Severe liver disease (Child-Pugh B or C)
  • Acute coronary syndrome, stroke, or hospitalization for decompensated heart failure within the past 3 months
  • Known hypersensitivity to alpha-lipoic acid or placebo excipients
  • Active malignancy or any condition that would prevent completing 12 weeks of follow-up
  • eGFR below 45 mL/min/1.73 m2
  • Pregnancy, lactation, or planned pregnancy
  • Current or recent (within 4 weeks) use of alpha-lipoic acid, other high-dose antioxidant supplements, or insulin

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 30 and 70 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to test whether adding alpha-lipoic acid (ALA) to usual treatment with metformin and dapagliflozin improves insulin resistance in adults with type 2 diabetes mellitus. The main questions it aims to answer are:

Read full original descriptionShow less

* Does ALA 600 mg once daily for 12 weeks lower insulin resistance, measured by the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), more than a placebo? * Does ALA also improve blood sugar control, body weight and waist size, blood pressure, and blood fats, and is it safe and well tolerated?

Participants will:

* Keep taking their usual metformin and dapagliflozin 10 mg daily without any change. * Take one capsule every day for 12 weeks, either ALA 600 mg or a matching placebo (a capsule with no active ingredient), assigned by chance. * Visit the clinic at the start, at week 6, and at week 12 for blood tests, body measurements, and safety checks.

Researchers will compare the ALA group with the placebo group to see if ALA lowers HOMA-IR more than placebo.

The 2 groups in the trial

  • ALA + Metformin/DapagliflozinExisting treatment, for comparison

    Alpha-lipoic acid 600 mg capsule taken orally once daily for 12 weeks, in addition to the participant's usual metformin and dapagliflozin 10 mg daily, which continue unchanged.

    Treatment: Alpha-Lipoic Acid (ALA)

  • Placebo + Metformin/DapagliflozinPlacebo, for comparison

    Matching placebo capsule taken orally once daily for 12 weeks, in addition to the participant's usual metformin and dapagliflozin 10 mg daily, which continue unchanged.

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Alpha-Lipoic Acid as Add-on Therapy to Dapagliflozin on Insulin Resistance and Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Criteria questions
Built from NCT07934225, who can take part
Record updated
12 November 2026